

Burden of illness among US Medicare beneficiaries with late-onset Huntington's disease



Jamie T Ta,¹ Sheila Reiss Reddy,² Anisha M Patel,¹ Eunice Chang,² Alex Exuzides,¹ Rita Gandhi,¹ George Yohrling³

(1) Genentech Inc, South San Francisco, CA, USA;

(2) Partnership for Health Analytic Research (PHAR), LLC, Beverly Hills, CA, USA;

(3) Huntington's Disease Society of America (HDSA), New York, NY, USA.

Genentech
A Member of the Roche Group

What does this study mean for the Huntington's disease (HD) community?

People with late-onset Huntington's disease (LoHD) can require extensive care, yet there is little information about the burden of illness in LoHD. We address this knowledge gap by describing the extent of healthcare resource utilization (HRU) and costs among US Medicare beneficiaries with LoHD. Our results highlight a significant unmet medical need within this HD population.

Objective

To examine healthcare resource utilization (HRU) and costs among US Medicare beneficiaries with late-onset Huntington's disease (LoHD).

Conclusions

- Medicare beneficiaries with late-onset Huntington's disease (HD) had greater healthcare resource utilization and higher costs compared with beneficiaries without HD over 3 years post-index.
- These results highlight a significant unmet medical need within this HD population.

BACKGROUND

- Huntington's disease (HD) is a rare, genetic neurodegenerative disease that is ultimately fatal and has a devastating impact on families across generations.^{1,2}
- HD is typically diagnosed between the ages of 30 and 50 years, but 4.4–11.5% of affected individuals are over 60 years at disease onset (late-onset HD [LoHD]).^{2,3}
- Although people with LoHD can require extensive care, limited evidence exists for the burden of illness in LoHD.
- This study describes healthcare resource utilization (HRU) and costs among US Medicare beneficiaries with LoHD.

METHODS


- This was a retrospective, longitudinal cohort study using 2008–2017 Medicare Research Identifiable Files (100%).
- We identified Medicare beneficiaries with newly diagnosed LoHD, defined as:
 - having one or more medical claims with an HD diagnosis between 2009 and 2014
 - being at least 60 years old at first HD diagnosis (index date) and having no HD claims for 1 year prior to the index date.
- We identified beneficiaries without HD (controls) using a 5% random sample of Medicare beneficiaries, who were matched to beneficiaries with LoHD 1:1 on age, sex, geographic region, and index year.
- All beneficiaries were continuously enrolled in Medicare fee-for-service (FFS) Part A/B and Part D for 1 year before and 3 years after the index date.
- Baseline demographic and clinical characteristics were measured during the 1-year pre-index period.
- We measured all-cause HRU and costs (in 2017 US dollars) over 3 years post-index and compared groups using chi-square tests (categorical variables) and t-tests (continuous variables).
- Among LoHD beneficiaries, all-cause and HD-related HRU and costs were further stratified by disease stage (early/middle/late) as determined by the presence of disease markers (i.e. diagnoses and services) in claims (**see results in Supplementary materials**).⁴

RESULTS

Baseline demographics and comorbidities

- A total of 2,652 Medicare beneficiaries were included in the analysis (1,326 with LoHD and 1,326 controls).
- Beneficiaries were mostly female (64.4%) and had a mean (standard deviation [SD]) age of 74.7 (7.4) years.
- LoHD beneficiaries had a higher mean Charlson Comorbidity Index (CCI) and prevalence of anxiety, dementia, and depression than controls (**Figure 1**).

Figure 1. Baseline comorbidities




LoHD beneficiaries had higher prescription drug use compared with matched controls

- The use of antidepressants, anxiolytics, anti-epileptics, and antispasticity drugs was higher in LoHD beneficiaries compared with controls in Years 1–3 post-index (**Figure 2**).

Limitations

- Our study was limited to the Medicare FFS population; therefore, these results may not be generalizable to individuals enrolled in Medicare-managed care plans or other types of insurance (e.g. commercial, Medicaid).
- Our analysis of Medicare claims data did not consider indirect costs and may not fully capture disease burden among Medicare beneficiaries with LoHD.

Figure 2. Prescription drug use



At Years 1–3 post-index, all-cause HRU and healthcare costs remained significantly higher among LoHD beneficiaries compared with matched controls (Figure 3 and 4)

- A higher proportion of LoHD beneficiaries had hospitalizations, emergency department (ED) visits, skilled nursing facility (SNF) stays, and durable medical equipment (DME) utilization than matched controls (**Figure 3**).
- Mean (SD) office visits was higher in LoHD beneficiaries compared with controls (Year 1: 18.0 [15.4] vs. 13.4 [11.6]; Year 2: 16.0 [14.8] vs. 13.8 [12.6]; Year 3: 15.5 [15.2] vs. 13.9 [12.7]; all p<0.01).
- Higher mean annual total costs for LoHD beneficiaries were driven by higher outpatient medical costs (**Figure 4**).

Figure 3. All-cause HRU





Figure 4. Mean all-cause healthcare costs



*p<0.001. Inpatient costs: acute hospitalization, SNF, and hospice services; Outpatient costs: outpatient hospital, ED, office, lab, or other outpatient services. Pharmacy costs represented outpatient pharmacy costs.

Acknowledgments

This study is funded by Genentech Inc. The authors thank Jen Ciarochi, of Meditech Media (US), for providing editorial support for this poster, which was funded by E. Hoffmann-La Roche Ltd in accordance with Good Publication Practice (GPP3) guidelines (<http://www.ismpp.org/gpp3>).

Abbreviations

CCI, Charlson Comorbidity Index; DME, durable medical equipment; ED, emergency department; FFS, fee-for-service; HD, Huntington's disease; HRU, healthcare resource utilization; LoHD, late-onset HD; SD, standard deviation; SNF, skilled nursing facility; USD, United States dollars.

References

- Bates GP, et al. *Nat Rev Dis Primers*. 2015; 1:15005;
- Roos RA. *Orphanet J Rare Dis*. 2010; 5:40;
- Chaganti SS, et al. *J Huntingtons Dis*. 2017; 6:95–103;
- Divino V, et al. *JME*. 2013; 16:1043–1050.



To access the full poster on your mobile device, including any supplementary materials, please scan using your QR reader application. NB: there may be associated costs for downloading data. These costs may be high if you are using your smartphone abroad. Please check your mobile data tariff or contact your service provider for more details. Alternatively this can be accessed at: <https://bit.ly/3bEYqoc>.

Burden of illness among US Medicare beneficiaries with late-onset Huntington's disease

Jamie T Ta,¹ Sheila Reiss Reddy,² Anisha M Patel,¹ Eunice Chang,² Alex Exuzides,¹ Rita Gandhi,¹ George Yohrling³

(1) Genentech Inc, South San Francisco, CA, USA;

(2) Partnership for Health Analytic Research (PHAR), LLC, Beverly Hills, CA, USA;


(3) Huntington's Disease Society of America (HDSA), New York, NY, USA.



Genentech
A Member of the Roche Group


SUPPLEMENTARY MATERIALS

Supplementary Figure 1. Prescription drug use stratified by HD stage



HD treatment includes the following: tetrabenazine, deutetabenazine, glutamatergic-modifying drugs, donepezil, minocycline, nabilone, coenzyme Q10, neuroleptics, energy metabolites.

Supplementary Figure 2. Mean all-cause and HD-related total healthcare costs stratified by HD stage



Costs include inpatient, outpatient and pharmacy costs. ** Claims with any diagnosis of HD, HD symptoms or HD treatment.

Supplementary Table. All-cause and HD-related HRU stratified by HD

	Early-stage (n=457)	Middle-stage (n=430)	Late-stage (n=439)	P-value
Year 1				
All-cause hospitalizations, n (%)	56 (12.3)	116 (27.0)	251 (57.2)	<0.001
All-cause ED visits, n (%)	96 (21.0)	175 (40.7)	208 (47.4)	<0.001
All-cause office visits, mean (SD)	14.8 (11.4)	20.3 (16.2)	19.1 (17.5)	<0.001
HD-related* hospitalizations, n (%)	27 (5.9)	71 (16.5)	160 (36.4)	<0.001
HD-related* ED visits, n (%)	21 (4.6)	39 (9.1)	73 (16.6)	<0.001
HD-related* office visits, mean (SD)	1.9 (4.6)	2.2 (3.5)	2.6 (5.2)	0.076
Year 2				
All-cause hospitalizations, n (%)	84 (18.4)	93 (21.6)	132 (30.1)	<0.001
All-cause ED visits, n (%)	126 (27.6)	142 (33.0)	168 (38.3)	0.003
All-cause office visits, mean (SD)	14.8 (12.1)	17.3 (15.5)	16.0 (16.4)	0.035
HD-related* hospitalizations, n (%)	32 (7.0)	46 (10.7)	75 (17.1)	<0.001
HD-related* ED visits, n (%)	31 (6.8)	29 (6.7)	48 (10.9)	0.033
HD-related* office visits, mean (SD)	1.2 (3.1)	1.6 (3.9)	1.7 (3.8)	0.147
Year 3				
All-cause hospitalizations, n (%)	80 (17.5)	101 (23.5)	148 (33.7)	<0.001
All-cause ED visits, n (%)	118 (25.8)	156 (36.3)	166 (37.8)	<0.001
All-cause office visits, mean (SD)	15.2 (12.3)	17.1 (17.3)	14.4 (15.6)	0.027
HD-related* hospitalizations, n (%)	34.0 (7.4)	54 (12.6)	94 (21.4)	<0.001
HD-related* ED visits, n (%)	27 (5.9)	39 (9.1)	53 (12.1)	0.005
HD-related* office visits, mean (SD)	1.3 (3.4)	1.7 (4.8)	1.6 (3.7)	0.325

*Claims with any diagnosis of HD, HD symptoms or HD treatment.

Acknowledgments

This study is funded by Genentech Inc. The authors thank Jen Ciarochi, of Meditech Media (US), for providing editorial support for this poster, which was funded by F. Hoffmann-La Roche Ltd in accordance with Good Publication Practice (GPP3) guidelines (<http://www.ismpp.org/gpp3>).

Abbreviations

ED, emergency department; HD, Huntington's disease; HRU, healthcare resource utilization; SD, standard deviation; USD, United States dollars.



To access the full poster on your mobile device, including any supplementary materials, please scan using your QR reader application. NB: there may be associated costs for downloading data. These costs may be high if you are using your smartphone abroad. Please check your mobile data tariff or contact your service provider for more details. Alternatively this can be accessed at: <https://bit.ly/3bEYqoc>.